PFS in midgut vs pancreatic NET
0 3 6 9 12
18
24 27
0
10
20
30
40
50
60
70
80
90
100
Time, months
Lanreotide Autogel 120mg
8
events
/ 33 patients
m
edian, not
reached
Placebo
21 events / 40 patients
median, 21.1 months [95% CI: 17.0, NC]
Midgut NETs (n =73)
Lanreotide Autogel vs
placebo
P
=
.0091
HR = 0.35 [95% CI: 0.16, 0.80]
0
10
20
30
40
50
60
70
80
90
100
Time, months
Lanreotide Autogel 120mg
18 events
/ 42 patients
median, not
reached
Placebo
31 events / 49 patients
median, 12.1 months [95% CI: 9.4, 18.3]
pNETs (n = 91)
Lanreotide Autogel vs
placebo
P
=
.0637
HR = 0.58 [95% CI: 0.32, 1.04]
0 3 6 9 12
18
24 27
Patients Alive and With No Progression, %
Caplin ME, et al.
N Engl J Med.
2014
CLARINET: LANREOTIDE PROLONG PFS IN
ENTEROPANCREATIC NET
